Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelegy for Symptomatic COPD in China
CTR20222010Phase 4Completed
- Sponsor
- GSK
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Aug 2022; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20222010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222010.